Camrelizumab, initially known as SHR-1210, represents a significant advancement in cancer treatment, functioning as a biologic that blocks the programmed death-1 receptor. This checkpoint protein, expressed on immune cells , normally suppresses anti-tumor immune responses, allowing tumor cells to evade recognition by the body’s immune system . By